WEATHERWAX BIOTECHNOLOGIES CORPORATION

Biotech · Private

Bifunctional molecules that reactivate tumor suppressor functions of mutant p53 proteins in triple-negative breast cancer

Grants
$400K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
5
0 granted · 5 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Development of Heterobivalent Small-Molecule Therapeutics for the Treatment of Triple-Negative Breast Cancer$296,286
Federal grantDepartment of Health and Human Services · Phase I · Development of Heterobivalent Small-Molecule Therapeutics for the Treatment of Triple-Negative Breast Cancer$103,714
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1363CALISTA THERAPEUTICS INC——
1364DOOR PHARMACEUTICALS, LLC——
1365ADECTO PHARMACEUTICALS, INC.——
1366WEATHERWAX BIOTECHNOLOGIES CORPORATION——
1367NANO BIOTHERAPEUTICS INC——
1368ARTUS THERAPEUTICS INC.——
1369Curebiotech, Inc.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 5
  • Targeted Protein Modificationapplication
  • Targeted Protein Modificationapplication
  • Targeted Protein Modificationapplication
  • Targeted Protein Modificationapplication
  • Targeted Protein Modificationapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.